Celldex Therapeutics, Inc. CLDXincurred first-quarter 2018 loss (excluding goodwill impairment charges) of 19 cents per share, wider than the Zacks Consensus Estimate of a loss of 17 cents but narrower than the year-ago loss of 28 cents. Lower costs and higher revenues led to the year-over-year improvement.
Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться